Drugs / NK cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05461235 | Jul 2022 → Jul 2025 | digestive system cancer | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT05171309 | Jan 2021 → Dec 2022 | hepatocellular carcinoma | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK-Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05461235 ↗ |
| Modality | Cell therapy | “Cord blood derived NK cells 4 cycles” NCT05171309 ↗ |
| Route | Intravenous | “continuous intravenous infusion for 2 days every 14±2 days” NCT05171309 ↗ |